UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2007
EUGENE SCIENCE, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 000-50601 | | 33-0827004 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
8th Floor, LG Palace Building, 165-8 Donggyo-Dong, Mapo-Gu, Seoul, Korea | | 00000 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: 82-2-338-6283
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
EXPLANATORY NOTE
This Amendment No. 1 to the Current Report on Form 8-K filed July 6, 2007 is being filed to (i) amend and restate the disclosure made in Item 1.01, (ii) add the disclosure required by Item 3.02 and (iii) include the exhibits required by Item 9.01 and Item 601 of Regulation S-B.
Item 1.01 Entry into a Material Definitive Agreement.
On July 2, 2007, Eugene Science, Inc. (the “Company”) entered into a Note and Warrant Purchase Agreement (the “Agreement”) with an accredited investor (the “Investor”), whereby the Company sold and issued, and the Investor purchased, a senior secured promissory note in the aggregate principal amount of $750,000 (the “Note”) and warrants to purchase 2,050,000 shares of the Company’s common stock at an exercise price of $0.25 per share (the “Warrants”). The Note bears interest at a rate of 10% per annum and, at the option of the Investor, is convertible into shares of the Company’s common stock during the first six months following the issue date of the Note at a conversion price of $0.65. The Warrants will be exercisable for shares of the Company’s common stock at any time on or after July 2, 2007 and at or before 5:00 p.m., Pacific time, on July 2, 2010.
The Note matures on January 2, 2008 (the “Maturity Date”), subject to up to three extensions of the Maturity Date as set forth in the Agreement. Upon an event of default under the Note, the Investor has the ability to declare all outstanding obligations under the Note immediately due and payable. Generally, an event of default includes (a) the Company’s failure to pay when due any monetary obligation under the Note, (b) the Company’s breach of any representation, warranty, covenant or other provision under the Note or the Agreement, which, if capable of being cured, is not cured within 10 days following notice thereof, (c) the application for the appointment of a receiver or custodian for the Company, (d) the entry of an order for relief or the filing of a petition by or against the Company under the provisions of any bankruptcy or insolvency law, or (e) the insolvency of the Company. To secure the Company’s repayment obligations under the Note, the Investor obtained a first priority security interest in all of the Company’s assets.
This announcement is not an offer to sell either the Note, the Warrants or the shares of the Company’s common stock issuable upon conversion of the Note or exercise of the Warrants. Neither the Note, the Warrants nor the shares of the Company’s common stock issuable upon conversion of the Note or exercise of the Warrants have been registered under the Securities Act of 1933, as amended, and the foregoing may not be offered or sold in the United States absent registration or availability of an applicable exemption from registration.
The foregoing descriptions of the Agreement, the Note and the Warrants do not purport to be complete and are qualified in their entirety by reference to the Agreement, the Note and the Warrants, copies of which are filed herewith as Exhibits 10.1, 10.2 and 10.3, respectively.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
See the disclosure set forth under Item 1.01, which is incorporated by reference into this Item 2.03.
Item 3.02 Unregistered Sales of Equity Securities.
See the disclosure set forth under Item 1.01, which is incorporated by reference into this Item 3.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | | Description |
| 10.1 | | Form of Note and Warrant Purchase Agreement, dated as of July 2, 2007, by and between Eugene Science, Inc. and the investor named therein. |
| | | |
| 10.2 | | Form of Secured Senior Promissory Note. |
| | | |
| 10.3 | | Form of Common Stock Purchase Warrant. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | EUGENE SCIENCE, INC. |
| | |
| | |
| Date: November 16, 2007 | /s/ Seung Kwon Noh |
| | Seung Kwon Noh |
| | President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit Number | | Description |
| 10.1 | | Form of Note and Warrant Purchase Agreement, dated as of July 2, 2007, by and between Eugene Science, Inc. and the investor in the offering. |
| | | |
| 10.2 | | Form of Secured Senior Promissory Note. |
| | | |
| 10.3 | | Form of Common Stock Purchase Warrant. |
